Gatifloxacin

Abstract

Gatifloxacin has an extended spectrum of antibacterial activity and provides better coverage of Gram-positive organisms (e.g. S. pneumoniae) than some older fluoroquinolones. The drug has favourable pharmacokinetic properties, is administered once daily and is at least as well tolerated as other fluoroquinolones. Gatifloxacin is a useful addition to the fluoroquinolones currently available for use in the clinical setting and has an important role in the management of adult patients with various bacterial infections. As with other fluoroquinolones, careful control of gatifloxacin usage in the community is important in order to prevent the emergence of bacterial resistance and thus preserve the clinical value of this agent.

Stimuli‐Responsive Delivery of Antimicrobial Peptides Using Polyelectrolyte Complexes

“…The first reported pH‐responsive polyelectrolyte complex nanoparticles were derived from tannic acid that, much like the system developed by Sukhishvili and coworkers for surfaces, [ 43 ] was used to prepare nano systems capable of encapsulating either an AMP—colistin sulphate [ 19 ] —or one of two aminoglycoside antibiotics, gentamicin [ 49 ] and gatifloxacin. [ 58 ] Out of the three antimicrobials tested, the nanoparticles containing colistin sulphate were the most stable at pH 7.4, with only ≈39% of the drug being released at this pH. However, at pH 4.5 the electrostatic interactions between the AMP and the tannic acid were neutralized, leading to complete particle disassembly, and the release of ≈98% of the AMP in < 2 h of incubation.…”

The New Gatifloxacin‐p‐Coumaric Acid Cocrystalline Form for Enhanced In Vitro Pharmaceutical Properties While Improving Oral Bioavailability and Antibacterial Activity

“…As the fourth-generation fluoroquinolone antibiotic, gatifloxacin (GAT, Scheme 1) is generally applied in the treatment of various bacterial infections caused by gram-negative and gram-positive bacteria, especially against drug-resistant streptococcus and staphylococcus pathogens. [4,5] However, as with most fluoroquinolones, GAT performs a neutral form due to proton transfer between the piperazine ring and the carboxyl group, resulting in poor solubility, [6][7][8] which limits its clinical efficacy to some extent. [9] To further develop this drug, a number of approaches have been explored to address these looming deficiencies, largely focusing on pharmaceutical methods and structural modifications.…”

Advantages of Cubosomal Formulation for Gatifloxacin Delivery in the Treatment of Bacterial Keratitis: In Vitro and In Vivo Approach Using Clinical Isolate of Methicillin-Resistant Staphylococcus aureus

“…Gatifloxacin (GTX) is a fourth generation fluoroquinolone antibacterial used for treatment of ocular infections through inhibiting bacterial DNA replication, transcription and repair [14,15]. Compared to other quinolones, GTX is more effective with broader spectrum especially in the case of staphylococcus and streptococcus infections [16]. However, the use of GTX in ocular infections is limited by its sub-therapeutic concentrations in the corneal aqueous humour and iris-clarity body due to the reduced GTX permeability.…”